131I治疗分化型甲状腺癌的辐射防护

辐射防护通讯 ›› 2019, Vol. 39 ›› Issue (6): 14-18.

¹³¹I治疗分化型甲状腺癌的辐射防护

高洪波¹, 白靖¹, 李隆敏¹, 刘海春¹, 张晓勇¹, 邵玉军¹, 庞华²

1.北京核工业医院核素诊疗中心, 北京, 102413;
2.北京核工业医院质量控制办公室, 北京, 102413

收稿日期:2019-03-21 发布日期:2019-12-20
通讯作者: 庞华。phua2008@sina.com
作者简介:高洪波(1982—),男,2007年毕业于承德医学院临床医学专业,学士;2010年毕业于石河子大学医学院肿瘤学专业,医学硕士。副主任医师。主要从事核医学诊断及治疗工作。gaohongbo0007@163.com

Radiation Protection for Differentiated Thyroid Cancer Patients with ¹³¹I Therapy

Gao Hongbo¹, Bai Jing¹, Li Longmin¹, Liu Haichun¹, Zhang Xiaoyong¹, Shao Yujun¹, Pang hua²

1. Department of Radionuclide treatment center, Beijing Nuclear Industry Hospital, Beijing, 102413;
2. Quality control office,Beijing Nuclear Industry Hospital, Beijing, 102413

Received:2019-03-21 Published:2019-12-20

摘要/Abstract

摘要： 分化型甲状腺癌(DTC)患者甲状腺全切或近全切术后常需要对患者行¹³¹I治疗,¹³¹I单次治疗剂量超过400 MBq时,需住院隔离。随着DTC患者的不断增加,¹³¹I应用越来越广泛,应用量越来越大,辐射防护问题受到人们的广泛关注。本文从病房环境防护、患者自身防护、医护人员防护及周围人群防护等几方面介绍了¹³¹I治疗后患者住院期间及出院后应该采取的防护措施及应注意的一些事项,可以更好地保护患者、医护人员及公众的健康。

关键词: ¹³¹I治疗, 辐射防护, 分化型甲状腺癌

Abstract: Patients with differentiated thyroid cancer (DTC) often need ¹³¹I treatment after total or subtotal thyroidectomy. When a single dose of ¹³¹I exceeds 400 MBq, they need to be hospitalized for isolation. With the continuous increase of DTC patients, ¹³¹I treatment is becoming more and more widely used, and the amount of application is getting larger and larger. Associated radiation protection issue has thus attracted widespread attention. Some protective measures and matters, which need to be taken during and after ¹³¹I treatment, is presented from the aspects of ward environmental protection, patient self-protection, medical staff protection, and surrounding crowd protection. It’s intended to better protect of patients, medical staff and the public.

Key words: ¹³¹I therapy, Radiation protection, Differentiated thyroid cancer(DTC)

中图分类号:

TL75

高洪波, 白靖, 李隆敏, 刘海春, 张晓勇, 邵玉军, 庞华. ¹³¹I治疗分化型甲状腺癌的辐射防护[J]. 辐射防护通讯, 2019, 39(6): 14-18.

Gao Hongbo, Bai Jing, Li Longmin, Liu Haichun, Zhang Xiaoyong, Shao Yujun, Pang hua. Radiation Protection for Differentiated Thyroid Cancer Patients with ¹³¹I Therapy[J]. RADIATION PROTECTION BULLETIN, 2019, 39(6): 14-18.

参考文献

[1] Haugen B R M, Alexander E K, Bible K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer[S]. Thyroid,2016:26:1-133.
[2] Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, 2012[J]. Chin J Cancer Res, 2016,28(1):1-11.
[3] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华内分泌代谢杂志,2012,28:779-797.
[4] Ezzat S,Sarti D A,Cain D R,et al.Thyroid incidentalomas, Prevalence by palpation and uhrasonography[J].Arch Intern Med,1994,154:1838-1840.
[5] 核工业标准化研究所.电离辐射防护与辐射源安全基本标准:GB 18871—2002 [S]. 北京:中国标准出版社,2002.
[6] 中国医学科学院放射医学研究所,四川省疾病预防控制中心.临床核医学的患者防护与质量控制规范:GB 16361—2012 [S].北京:中国标准出版社,2012.
[7] 关海霞,吕朝晖. 解读甲状腺癌[M]. 沈阳:辽宁科学技术出版社,2014: 172-177.
[8] 中华医学会核医学分会. ¹³¹I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志,2014, 34:264-278.
[9] 陈宇导,张峰,吴春兴, 等. 核医学科核素治疗病房的辐射防护及管理[J]. 中华护理杂志,2014, 49(5):575-576.
[10] Ibis E, Wilson C R, Collier B D, et al. Iodine-131 contamination from thyroid cancer patients[J]. The Journal of Nuclear Medicine, 1992, 33(12): 2110-2115.
[11] 梁小明. ¹³¹I 治疗分化型甲状腺癌的放射防护[J]. 西部医学,2011, 2 (39): 1685-1688.
[12] 中华医学会核医学分会临床核医学辐射安全专家共识编写委员会. 临床核医学辐射安全专家共识[J]. 中华核医学与分子影像杂志,2017, 37(4):225-229.
[13] 刘长安,梁莉,郭鲜花, 等. 非密封放射性核素治疗后的患者出院考虑[M].北京:北京大学医学出版社, 2007:8-59.
[14] 匡安仁. ¹³¹I治疗分化型甲状腺癌[M]. 北京:人民卫生出版社,2013:355.
[15] Mathieu I, Caussin J, Smeesters P, et al. Doses in family members after ¹³¹I treatment[J]. Lancet, 1997, 350:1074-1075.
[16] Mathieu I, Caussin J, Smeesters P, et al. Recommended restrictions after iodine-131 therapy: measured doses in family members[J]. Health Phys, 1999, 76:129-136.
[17] International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides[R]. ICRP Publication 94.Stockholm:ICRP,2004.

¹³¹I治疗分化型甲状腺癌的辐射防护

Radiation Protection for Differentiated Thyroid Cancer Patients with ¹³¹I Therapy

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

Metrics

本文评价

推荐阅读 7

[1]	章诚, 张岭, 殷春许, 何廷贵, 何丽娟. DR机房建设与验收监测的要点探讨[J]. 辐射防护通讯, 2020, 40(1): 17-22.
[2]	刘书锋, 王利, 于丰萁, 殷爱民, 马得勋. 基层部队核事故应急防护与医学应急救援处置能力建设初步探讨[J]. 辐射防护通讯, 2020, 40(1): 23-26.
[3]	卞华慧, 王敏, 孙亮, 陈炜博, 王优优, 张玉松, 戴宏, 冯骏超, 魏静, 刘玉龙. 对某公司7例疑似受照放射工作人员的医学评估与思考[J]. 辐射防护通讯, 2020, 40(1): 1-5.
[4]	刘小强, 张希劲, 马得勋, 刘书锋. 辐射防护剂的研究进展[J]. 辐射防护通讯, 2019, 39(6): 1-5.
[5]	邱新宇, 闫玉洁, 奚可迪, 张琨岚, 胡文涛, 张健. 放射性骨丢失机制与防护研究进展[J]. 辐射防护通讯, 2019, 39(2): 23-33.
[6]	易于颦, 胡凤琼. 甲癌患者¹³¹I治疗出院标准及时间研究进展[J]. 辐射防护通讯, 2019, 39(2): 43-48.